The iPSC session April 29 in Los Angeles involves CIRM's Standards Working Group, which makes recommendations for rules for the agency's $3 billion research program. The meeting is a continuation of last year's session dealing with the banking of iPSCs. The goal of the meeting this year is to "recommend operational criteria that will assist CIRM in developing a request for proposal for the iPSC bank."
The draft agenda includes consent standards, withdrawal of subjects from research, transfer of materials and communication of results. The agenda said,
"The generation of iPSCs for disease modeling may results in published findings of interest to donors or individual results on research studies that would alter clinical management of donors. Under what conditions, if any, should information be returned to donors as groups or individuals?"Coming up on May 26 is a webinar on imaging technology that will feature panelists from the FDA, the NIH and industry. Moderating it will be Ellen Feigal, formerly of Amgen but now the new VP for research and development at CIRM.
The agenda includes the "FDA’s perspective on imaging technology, the use of imaging technology in preclinical studies to assess cell fate" and an overview of existing and new imaging technology.
The webinar, which is part of CIRM's Regenerative Medicine Consortium program, is free but requires advance registration.
iPS cells are man-made pluripotent cancer cells, created by the opponents of human embryonic stem cell (hESC) research so they can take a big chunk of CA Prop71, then spend other big chunk of CA prop71 to discover that the iPS cells actually have too many mutations to be clinically useful that were created in the first place. Also excuse CIRM to deem hESC research for the cure in CA to be illegible for Prop71 funding that was created to support hESC research in CA in the first place.
ReplyDelete